Yogee'S Bioinnovations Private Limited

Yogee'S Bioinnovation is a start-up company incubated at the Technology Business Incubator@ Birla Institute of Technology and Science-Pilani, Hyderabad campus. Founded in Feb 2015 as a spinoff of Department of Pharmacy, BITS-Pilani, Hyderabad.

The company is focussed on preclinical drug discovery and diagnostics covering a span of therapeutic areas including cancer, neuropathic pain including diabetic neuropathy, metabolic disorders, infectious diseases including TB and ESKAPE infections and neurological disorders. For disease diagnosis, the current focus is on oncology

Currently the company is promoted by two Founders, **Prof. P. Yogeeswari and Prof. D. Sriram** along with their research students. The founders have more than 14 years of experience in new drug discovery research with track of more than 200 international publications, three Indian patents filed and two in pipeline.

Founders



Prof. P. Yogeeswari received her Ph.D. degree in the year 2001 from Banaras Hindu University, Varanasi. She has been in the field of drug discovery for neurological diseases for the past 16 years and have completed sponsored projects worth of 3 crores of rupees including industrial consultancy. She has also been granted IASP 2014 award for "Excellence in Pain Research and Management in Developing Countries" under the basic science research category to be received at the "15th World Congress on Pain" at Argentina in October 2014. She has collaborations with various national and international organizations. **She has an active program with INSERM Pasteur Institute de Lille, France on Diabetes drug discovery.**

Prof. D. Sriram received his Ph.D. from Banaras Hindu University in the year 2000. He is an experienced Medicinal Chemist involved in new Drug Discovery research for more than 15 years with various sponsored grants worth of 4.5 crores of rupees including indo-international projects. He has to his credit various National recognition as awards and has a track record number of publications. His major therpeutic areas of interest include drug discovery for Tuberculoisis, and ESKAPE pathogenic infections.



PIPELINE PROGRAMS: Looking for Partners/Investors in developing drugs



